Dr. Rose on the Results of the BEAVER Trial in Non-V600E BRAF-Mutant Advanced Solid Tumors

Video

April Rose, MD, discusses the efficacy results of the ongoing phase 2 BEAVER trial in non-V600E BRAF-mutant advanced solid tumors.

April Rose, MD, assistant professor of oncology, Gerald Bronfman Department of Oncology, McGill University, discusses the efficacy results of the ongoing phase 2 BEAVER trial (NCT03839342) in non-V600E BRAF-mutant advanced solid tumors.

The BEAVER trial is an open-label, single-center study examining the use of binimetinib (Mektovi) plus encorafenib (Braftovi) in adult patients with advanced and/or metastatic solid tumors that harbor non-V600E BRAF mutations. Patients were a median age of 61 years and the majority had received at least 2 systemic therapies, Rose explains. Patients with a variety of different cancer types were enrolled on the study, including melanoma, colorectal, pancreatic, gallbladder, ampullary, breast, non–small cell lung, and uterine cancers, Rose adds.

Regarding efficacy, 2 of 11 patients responded with the combination of binimetinib and encorafenib, Rose continues. Additionally, 2 patients achieved stable disease, whereas all remaining patients developed progressive disease. This translated to an overall response rate of 18%, Rose concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,